Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731

ABI-H0731, a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity in chronic hepatitis B (CHB) patients in a phase 1b clinical trial and is currently being further evaluated in phase 2 clinical trials. Here, we report the preclinical profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qi, Cai, Dawei, Yan, Ran, Li, Lichun, Zong, Yuhua, Guo, Lida, Mercier, Alexandre, Zhou, Yi, Tang, Ariel, Henne, Kirk, Colonno, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577125/
https://www.ncbi.nlm.nih.gov/pubmed/32868329
http://dx.doi.org/10.1128/AAC.01463-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577125/
https://www.ncbi.nlm.nih.gov/pubmed/32868329
http://dx.doi.org/10.1128/AAC.01463-20

Ejemplares similares